Peri-Implantitis: The Elephant in the Room
Peri-implantitis, a bone destructive and soft tissue disease– is a dental implant complication that affects more than 33% of patients and up to 43% of dental implants, with diabetics and smokers particularly at risk. Peri-implantitis can cause bone loss and implant failure.
Current Peri-Implantitis Treatments
Peri-implantitis treatments include local debridement and anti-infectious therapy. Sometimes a surgical procedure is necessary for more comprehensive debridement and attempted implant surface decontamination. It is not unusual for periimplantitis to result in implant failure and removal.
The Implant-B Breakthrough
Implant-B has developed a novel multi-piece implant with a removeable sleeve. It is inserted like any standard implant. However, if periimplantitis develops, the restoration is removed and the contaminated sleeve extracted. After tissue debridement (a standard protocol), a new, uncontaminated titanium sleeve is slipped over the implant and the original restoration returned.
The key benefits:
- Completely removes the contaminated surface area.
- Promotes maximal re-osteointegration.
- Re-use of the original restoration saves both time and money.
The Market Opportunity
The global dental implants and prosthetics market is expected to grow to ~USD 12.3B by 2021 at a CAGR of 7.2%, driven by a growing geriatric population, rising incidence of dental caries & periodontal diseases, growing disposable incomes and the rising demand for cosmetic dentistry. Value and premium implants currently make up ~84% of the dental implants market.
The Business Landscape
The dental implants and prosthetics market has a good mix of large- and medium sized global players. There are a number of Israeli companies already active in this market, including MIS Implants, which was recently acquired by Dentsply-Sirona for USD 375 M.
Leading dental players are focused on strategic acquisitions for technology innovation and market access, with several multi-billion-dollar transactions over the last three years.
There are strong opportunities for new entrants with specialized knowledge and innovative products.
The Management Team
Dr. Liat Chaushu, Founder & Director ,DMD, MSc in Clinical Periodontics.
Hagai Yehidi, CEO, over 6 years of managerial experience in Dental Market.
Zohar Gendler, BOD Chairman, Managing Partner & CEO of NGT3VC. Former CEO & director of Beta-O2 Technologies (developed proprietary implantable bio-artificial pancreas). Served as CEO of the Technion Technological Incubator for 11 years. Led the establishment and investment in 53 companies, such as Prolor Biotech (sold to OPKO, $480M), Mazor Robotics (Sold to Medtronic, $1.6B), ReWalk (NASDAQ: RWLK), Corindus (Sold to Siemens, $1.1B), and many others.
Scientific Advisory Board
Prof. Haim Tal, DMD, MDent, PhD ,Chairman of Dept. of Periodontology & Implantology, Tel-Aviv University
Prof. Gabi Chausho, DMD, MSc ,Director of Oral & Maxillofacial Surgery Dept., Rabin Medical Center, Israel
Prof. Samer Srouji, DMD, PhD ,Chief of Oral and Maxillofacial Dept., Galilee Medical Center, Israel
National phase entered September 2017 in: USA, Canada, Europe, Australia, China, Israel. Claims cover renewable outer surface to maintain initial implant and promote osseointegration.
For further information contact: